Expression of TEL-AML1 Fusion Transcripts and Response to Induction Therapy in Standard Risk Acute Lymphoblastic Leukemia

We prospectively examined the frequency of the t(12;21)TEL-AML1 fusion in 504 children with newly diagnosed standard risk ALL using RT-PCR assays. Cells from 95 patients (18.8%) were TEL-AML1+. There was a significantly higher frequency of pseudodiploidy among the TEL-AML1+ cases (39.4% versus 14.1%, P=0.001), primarily because structural abnormalities involving 12p and del(6q) occurred more frequently in the TEL-AML1+ group. TEL-AML1+ ALL was more sensitive to the induction chemotherapy than TEL-AML1- ALL. The percentage of “rapid early responders”, i.e., patients who achieved an M1 (< 5% blasts) or M2 (5–25% blasts) marrow status on day 7 of induction chemotherapy, was significantly higher among TEL-AML1+ cases. The quality of remission of RT-PCR positive cases was excellent, as evidenced by the very low to absent MRD burden of their end-of-induction bone marrow specimens. TEL-AML1+ patients also had an excellent early EFS outcome. The probability of EFS at 30 months from study entry were 98.9×1.0% for the TEL-AML1+ group and 92.1×1.5% for the TEL-AML1- group (P=0.0001). This prospective study significantly expands the knowledge gained from previous studies regarding the prognostic significance of t(12;21)TEL-AML1 fusion in pediatric ALL.

[1]  M. Greaves,et al.  Prenatal origin of acute lymphoblastic leukaemia in children , 1999, The Lancet.

[2]  P S Gaynon,et al.  Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  O. Hrusak,et al.  TEL/AML1 positivity in childhood ALL: average or better prognosis? , 1999, Leukemia.

[4]  P. Marynen,et al.  The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. , 1996, Blood.

[5]  N. Heerema,et al.  Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative. , 1997, Leukemia & lymphoma.

[6]  J. Whang‐Peng.  Chromosomal abnormalities in acute lymphoblastic leukemia: structural and numerical changes in 234 cases. , 1981, Cancer genetics and cytogenetics.

[7]  S. Raimondi.  Current Status of Cytogenetic Research in Childhood Acute Lymphoblastic Leukemia , 1993 .

[8]  J. Downing,et al.  TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Uckun,et al.  Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. , 1989, Blood.

[10]  N. Heerema,et al.  Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Downing,et al.  Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. , 1997, Blood.

[13]  P S Gaynon,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Association of Chromosome Arm 9p Abnormalities With Adverse Risk in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group , 2016 .

[14]  Jianxiang Wang,et al.  Transformation properties of the ETO gene, fusion partner in t(8:21) leukemias. , 1997, Cancer research.

[15]  C. Bloomfield,et al.  Chromosomal abnormalities in acute lymphoblastic leukemia. , 1981, Cancer research.

[16]  P. Hokland,et al.  Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real‐time RT‐PCR exemplified by t(12;21) TEL‐AML1 fusion transcript , 1999, Genes, chromosomes & cancer.

[17]  D. Gilliland,et al.  TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia , 1997, Leukemia.

[18]  H. Sather,et al.  Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D C Ward,et al.  Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Cavé,et al.  ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia , 1997, Leukemia.

[21]  E. Macintyre,et al.  High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. , 1995, Blood.

[22]  E. Macintyre,et al.  Fluorescence in situ hybridization analysis of masked (8;21)(q22;q22) translocations. , 1999, Cancer genetics and cytogenetics.

[23]  P. Marynen,et al.  TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). , 1995, Blood.

[24]  T. Golub,et al.  Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia , 1996, Molecular and cellular biology.

[25]  T. Golub,et al.  Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. , 1996, Current topics in microbiology and immunology.

[26]  M. Schrappe,et al.  Acute lymphoblastic leukemia of childhood: identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1. , 1996, Blood.

[27]  S. Shurtleff,et al.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. , 1995, Leukemia.

[28]  M. Greaves,et al.  Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Rowley,et al.  TEL-AML1 translocations with TEL and CDKN2 inactivation in acute lymphoblastic leukemia cell lines , 1996 .

[30]  H P Koeffler,et al.  TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. , 1996, Blood.

[31]  A. Borkhardt,et al.  Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion , 1999, Genes, chromosomes & cancer.

[32]  J. Downing,et al.  12p Abnormalities and the TEL Gene (ETV6) in Childhood Acute Lymphoblastic Leukemia , 1997 .

[33]  N. Heerema,et al.  Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  James M. Roberts,et al.  TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. , 1995, Blood.

[35]  P. Riegman,et al.  Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. , 1995, Oncogene.

[36]  J. Rowley.  The role of chromosome translocations in leukemogenesis. , 1999, Seminars in hematology.

[37]  C. Reynolds,et al.  Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood. , 1995, Blood.

[38]  T. Gu,et al.  Core-binding factor: a central player in hematopoiesis and leukemia. , 1999, Cancer research.

[39]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[40]  H. Sather,et al.  Early response to therapy and outcome in childhood acute lymphoblastic leukemia , 1997, Cancer.

[41]  M. Greaves,et al.  Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero. , 1999, Blood.

[42]  N. Heerema,et al.  Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies , 1998, Cancer.

[43]  P S Gaynon,et al.  Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia , 2000, Cancer.

[44]  G. Morgan,et al.  Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. , 2000, Blood.

[45]  N. Heerema,et al.  Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. , 1998, Blood.

[46]  J. Downing,et al.  Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup , 1999, Leukemia.

[47]  J. Rowley,et al.  Correlation between the ETV6/CBFA2 (TEL/AMLI) fusion gene and karyotypic abnormalities in children with B‐cell precursor acute lymphoblastic leukemia , 1996, Genes, chromosomes & cancer.

[48]  J. Weissenbach,et al.  Loss of heterozygosity in the chromosomal region 12p12-13 is very common in childhood acute lymphoblastic leukemia and permits the precise localization of a tumor-suppressor gene distinct from p27KIP1. , 1995, Blood.

[49]  G. Basso,et al.  The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occurring in children with Down syndrome , 1997, Leukemia.

[50]  Peter J. Schaap,et al.  Molecular characterization of the , 1997 .

[51]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[52]  P. Marynen,et al.  Molecular characterization of 12p abnormalities in hematologic malignancies: deletion of KIP1, rearrangement of TEL, and amplification of CCND2. , 1996, Blood.